The biopharmaceutical sector is known for its volatility. Long R&D cycles, difficult regulations and the risk of uncertainty in developing new drug treatments should be carefully weighed before investing. However, a select few biopharma plays have weathered the storm to produce an extensive catalog of promising treatments. Our latest addition to the Best Healthcare Dividend Stocks List has several leading products to treat autoimmune diseases, arthritis and cancer. Through its current and previous incarnations, it has an extensive track record of dividend payouts.
You can check out the Best Healthcare Dividend Stocks List to explore all the stocks.
Our pick reported double-digit sales growth from several products in the first quarter. Management also gave favorable guidance by raising full-year adjusted earnings expectations. Combined, these factors make our pick a promising play for yield-seeking investors.
To make room for our biopharma pick, we’ve booked profits and reduced our position in a leading medical device company. Additionally, we were forced to remove a managed healthcare and insurance company from the list.